Altogether, our results confirm that MK-8722 treatment does not impair the SARS-CoV-2-specific CD8+ T cell-mediated response against mucosal Caco2 cell infection but rather that both act in combination to reduce cell infection. The gene discussed is CD8A; the disease is infection.